Tremor in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 8, Issue 4, 2002, Pages 223-234

  Carr, J ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Parkinson's disease; Substantia nigra; Tremor

Indexed keywords

CLINICAL FEATURE; GLOBUS PALLIDUS; HUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; THALAMOCORTICAL TRACT; THALAMUS; TREMOR;

EID: 0036164533     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(01)00037-2     Document Type: Short Survey

References (157)

1. Parkinson's disease. First of two parts
2. Central mechanisms of tremor
3. Parkinson's disease. Second of two parts
4. Updating the functional model of the basal ganglia
5. The current model of basal ganglia organization under scrutiny
6. Consensus statement of the Movement Disorder Society on Tremor
7. 18F-dopa PET study
8. Dementia in idiopathic Parkinson's disease. Variables associated with its occurrence in 203 patients
9. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?
10. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease
11. 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: Correlations with the three main symptoms
12. The functional anatomy of basal ganglia disorders
13. D1/D2 Dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons
14. Neurotransmitters and neuromodulators in the basal ganglia
15. Striatal inhomogeneities and basal ganglia function
16. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones
17. Tremor in MPTP-induced parkinsonism
18. Dopamine, tremor, and Parkinson's disease
19. The connections of the dopaminergic system with the striatum in rats and primates: An analysis with respect to the functional and compartmental organization of the striatum
20. Dopamine in Parkinsons disease and other neurological disturbances
21. Mid dopaminergic cell loss in Parkinson's disease: Computer visualization
22. The anatomy and pigmentation of the human substantia nigra in relation to selective neuronal vulnerability
23. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease
24. Ageing and Parkinson's disease: Substantia nigra regional selectivity
25. Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson's disease and striatonigral degeneration
26. Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra
27. The neuropathologic basis of different clinical subgroups of Parkinson's disease
28. Positron emission tomographic studies of dopa-responsive dystonia and early-onset idiopathic parkinsonism
29. Hereditary progressive dystonia with marked diurnal fluctuation
30. Lessons from a remarkable family with dopa-responsive dystonia
31. Chronic manganese poisoning: Report of a case with autopsy
32. Chronic manganese poisoning: A neuropathological study with determination of manganese distribution
33. Manganism and idiopathic parkinsonism: Similarities and differences
34. Chronic manganese poisoning
35. Presynaptic and postsynaptic striatal dopaminergic function in manganese intoxication studied by positron emission tomography
36. Dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations
37. Disorders of movement and system degenerations
38. Progressive supranuclear palsy: Motor, neurobehavioral, and neuroophthalmic findings
39. Progressive supranuclear palsy. A heterogeneous degeneration involving the stem, basal ganglia and cerebellum with vertical gase and pseudobulbar palsy, nuchal dystonia and dementia
40. Progressive supranuclear palsy: Postmortem chemical analysis
41. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications
42. Striatonigral degeneration: A clinicopathological study
43. 11C-raclopride and positron emission tomography
44. Striatal dopamine D2 receptors in Parkinsons disease, striatonigral degeneration determined by positron emission tomography
45. Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: A positron emission tomography study
46. Pathological overlap in cases of parkinsonism associated with neurofibrillary tangles. A study of recent cases of postencephalitic parkinsonism and comparison with progressive supranuclear palsy and Guamanian parkinsonism-dementia complex
47. Sequelae of acute epidemic encephalitis
48. Epidemic encephalitis
49. The pathology of Parkinsonism
50. The progression of idiopathic Parkinson's disease is not explained by age-related changes. Clinical and pathological comparisons with post-encephalitic parkinsonian syndrome
51. Para-encephalitic parkinsonism. Report of an acute case due to coxsackie virus type B 2 and re-examination of the etiologic concepts of postencephalitic parkinsonism
52. Postencephalitic parkinson syndrome after meningoencephalitis due to Coxsackie virus Group B. Type 2
53. Encephalitis and Parkinsonism
54. Individual manifestations of Parkinson's disease after ten or more years of levodopa
55. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs
56. Opposite motor effects of pallidal stimulation in Parkinson's disease
57. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis
58. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Seven cases
59. Chronic parkinsonism secondary to intravenous injection of meperidine analogues
60. 1-Methyl-4-phenyl-2,3,6-tetra-hydrophyridine-induced parkinsonian syndrome in 'Macaca Fascicularis': Which mid dopaminergic neurons are lost?
61. Injury of nigral neurons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A tyrosine hydroxylase immunocytochemical study in monkey
62. Treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease
63. Distinct nigrostriatal projection systems innervate striosomes and matrix in the primate striatum
64. The neostriatal mosaic: Compartmentalization of corticostriatal input and striatonigral output systems
65. Early-stage loss of dopamine uptake-site binding in MPTP-treated monkeys
66. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus
67. Pathophysiology of parkinsonian motor abnormalities
68. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism
69. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
70. The organization of mid projections to the ventral striatum in the primate
71. Organization of the ascending striatal afferents in monkeys
72. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism
73. MPTP-induced parkinsonism in primates: Pattern of striatal dopamine loss following acute and chronic administration
74. Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: Behavioural, morphological and biochemical correlates
75. Dopamine receptor changes in untreated and (+)-PHNO-treated MPTP parkinsonian primates
76. Symptomatic and Asymptomatic 1-Methyl-4-Phenyl-1,2,3,6- Tetrahydropyridine treated primates: Biochemical changes in striatal regions
77. The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease
78. Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP
79. Changes in catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys
80. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of monoamines in the rhesus monkey
81. Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism
82. The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
83. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice
84. The heterogenity of the mesostriatal dopaminergic system as revealed in normal and parkinsonian monkeys
85. Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons
86. Positron emission tomography after MPTP: Observations relating to the cause of Parkinson's disease
87. The functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease
88. Re-emergent tremor of Parkinson's disease
89. Neuronal basis of the parkinsonian resting tremor: A hypothesis and its implications for treatment
90. The subthalamic nucleus and tremor in Parkinson's disease
91. Microcircuitry of the direct and indirect pathways of the basal ganglia
92. Cholinergic systems in the rat: III. Projections from the pontomesencephalic tegmentum to the thalamus, tectum, basal ganglia, and basal fore
93. Pharmacological properties of acetylcholine-induced excitation of subthalamic nucleus neurones
94. The subthalamic nucleus and the external pallidum: Two tightly interconnected structures that control the output of the basal ganglia in the monkey
95. Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate
96. Re-evaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states
97. Evidence for a dopaminergic innervation of the subthalamic nucleus in the rat
98. Dopaminergic stimulation of subthalamic nucleus elicits oral dyskinesia in rats
99. Dopaminergic innervation of the basal ganglia in the squirrel monkey as revealed by tyrosine hydroxylase immunohistochemistry
100. Dopaminergic mechanisms in subthalamic nucleus of rat: Analysis using horseradish peroxidase and microiontophoresis
101. Tyrosine hydroxylase-immunoreactive elements in the human globus pallidus and subthalamic nucleus
102. Apomorphine and dopamine D(1) receptor agonists increase the firing rates of subthalamic nucleus neurons
103. Subthalamic responses to amphetamine and apomorphine in the behaving rat with a unilateral 6-OHDA lesion in the substantia nigra
104. Evidence for a distinct nigropallidal dopaminergic projection in the squirrel monkey
105. Relative sparing of the dopaminergic innervation of the globus pallidus in monkeys made hemi-parkinsonian by intracarotid MPTP infusion
106. The dopaminergic nigropallidal projection in primates: Distinct cellular origin and relative sparing in MPTP-treated monkeys
107. Neurons projecting from the entopeduncular nucleus to the thalamus receive convergent synaptic inputs from the subthalamic nucleus and the neostriatum in the rat
108. Convergence of subthalamic and striatal efferents at pallidal level in primates: An anterograde double-labeling study with biocytin and PHA-L
109. Evidence for interconnections between the two segments of the globus pallidus in primates: A PHA-L anterograde tracing study
110. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop
111. Anatomical aspects of information processing in primate basal ganglia
112. Basal ganglia and movement disorders: And update
113. Excitotoxic acid lesions of the primate subthalamic nucleus result in reduced pallidal neuronal activity during active holding
114. Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus
115. Treatment of tremor in Parkinson's disease by subthalamic stimulation
116. Responses of pallidal neurons to striatal stimulation in monkeys with MPTP-induced parkinsonism
117. Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: An in situ hybridization study of cytochrome oxidase subunit I mRNA
118. Glutamic acid decarboxylase mRNA expression in medial and lateral pallidal neurons in the MPTP-treated monkey and patients with Parkinson's disease
119. Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism
120. Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism
121. Unilateral lesion of the nigrostriatal pathway decreases the firing rate and alters the firing pattern of globus pallidus neurons in the rat
122. Characteristics of pallidal neuronal discharges in Parkinson's disease patients
123. Single-unit analysis of the pallidum, thalamus and subthalamic nucleus in parkinsonian patients
124. Identification and characterization of neurons with tremor- frequency activity in human globus pallidus
125. Functional and pathophysiological models of the basal ganglia
126. Physiology of MPTP tremor
127. The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism
128. Effect of GPi pallidotomy on motor function in Parkinson's disease
129. Neurons in the globus pallidus do not show correlated activity in the normal monkey, but phase-locked oscillations appear in the MPTP model of parkinsonism
130. A basal ganglia pacemaker formed by the subthalamic nucleus and external globus pallidus
131. Stimulation of subthalamic nucleus alleviates tremor in Parkinson's disease
132. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease
133. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease
134. Bilateral high-frequency stimulation of the internal globus pallidus in advanced Parkinson's disease
135. Differential neuronal activity in segments of globus pallidus in Parkinson's disease patients
136. Projection from the external pallidum to the reticular thalamic nucleus in the squirrel monkey
137. Basic mechanisms of generalized absence seizures
138. Contralateral pallidothalamic and pallidotegmental projections in primates: An anterograde and retrograde labeling study
139. Cellular mechanisms of a synchronised oscillation in the thalamus
140. Generalized epilepsy: Some of its cellular mechanisms differ from those of focal epilepsy
141. Petit mal epilepsy and parkinsonian tremor: Hypothesis of a common pacemaker
142. Effects of interruption of the nigrostriatal pathway and of dopaminergic agents on the spontaneous activity of globus pallidus neurons in the awake monkey
143. Patterns of bursting occurring in thalamic cells during parkinsonian tremor
144. Projections of the cerebellar and dorsal column nuclei upon the thalamus of the rhesus monkey
145. Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus
146. High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor
147. Single unit analysis of the human ventral thalamic nuclear group. Tremor-related activity in functionally identified cells
148. The role of the thalamus and basal ganglia in parkinsonian tremor
149. Long-term thalamic stimulation in Parkinson's disease: Postmortem anatomoclinical study
150. The metabolic anatomy of tremor in Parkinson's disease
151. Evidence for a common network of structures involved in parkinsonian tremor and voluntary repetitive movement
152. Stereotactic thalamotomy in tremor-dominant Parkinson's disease: An H2(15)O PET motor activation study
153. Thalamic stimulation and suppression of parkinsonian tremor. Evidence of a cerebellar deactivation using positron emission tomography
154. Globus pallidus stimulation activates the cortical motor system during alleviation of parkinsonian symptoms
155. Function of the cerebellum in Parkinsonian rest tremor and Holmes' tremor